We have not explained this story yet. The original headline, summary and link are below.

Charles River Laboratories International (CRL) is currently trading slightly below its average analyst target and close to its intrinsic value, with a "most followed narrative" pegging its fair value at $305.00, suggesting it is 5% undervalued. The company's investments in new methodologies and digitalization are seen as mitigating risks and supporting future margins, despite potential pressures from weak R&D funding or a shift away from animal testing. A discounted cash flow model suggests its future cash flows are just below its current share price, indicating a narrow margin of safety.